Zobrazeno 1 - 10
of 330
pro vyhledávání: '"Giovanni Marchegiani"'
Autor:
Leo Buhler, MD, Ty Dunn, MD, Ugo Boggi, MD, Charles Vollmer, MD, Jens Werner, MD, Christos Dervenis, MD, Giovanni Marchegiani, MD, Shailesh V. Shrikhande, MD, Igor Khatkov, MD, Abraham Fingerhut, MD
Publikováno v:
Annals of Surgery Open, Vol 5, Iss 1, p e393 (2024)
Externí odkaz:
https://doaj.org/article/640dc6591f9644b4b02cb3f0b788b110
Autor:
Fortunato Cassalia, Anna Bolzon, Monica Ponzano, Laura Ventura, Andrea Danese, Paolo Del Fiore, Anna Belloni Fortina, Elio Jovine, Giampaolo Perri, Umberto Cillo, Giovanni Marchegiani
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 1, p 104 (2023)
Background: Pancreatic cancer is notorious for its aggressive nature and low survival rate, with less than 10% of patients surviving beyond five years. Early detection is difficult, but skin metastases can be a rare but significant indicator. This sy
Externí odkaz:
https://doaj.org/article/ce02e3e05fbf4ed7b3b9872c40fffab8
Publikováno v:
Cancers, Vol 15, Iss 9, p 2499 (2023)
Pancreaticoduodenectomy (PD) is a mainstay in the management of periampullary tumors. Treatment algorithms increasingly employ a multimodal strategy, which includes neoadjuvant and adjuvant therapies. However, the successful treatment of a patient is
Externí odkaz:
https://doaj.org/article/47242df6cf15478bb84dcf1a7cfad3bf
Autor:
Salvatore Paiella, Giuseppe Malleo, Nicola Simoni, Renato Micera, Stefania Guariglia, Carlo Cavedon, Giovanni Marchegiani, Alessandro Esposito, Luca Landoni, Luca Casetti, Massimiliano Tuveri, Michele Milella, Erica Secchettin, Gessica Manzini, Chiara Bovo, Matteo De Pastena, Martina Fontana, Roberto Salvia, Renzo Mazzarotto, Claudio Bassi
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background The current management guidelines recommend that patients with borderline resectable pancreatic adenocarcinoma (BRPC) should initially receive neoadjuvant chemotherapy. The addition of advanced radiation therapy modalities, includ
Externí odkaz:
https://doaj.org/article/ab9b18350a4a446b89b3789e7bd7f7a9
Publikováno v:
Gut and Liver, Vol 13, Iss 2, Pp 149-153 (2019)
The International Study Group for Pancreatic Fistula (ISGPF) made the first attempt to standardize the outcome measure of fistulas in the field of pancreatic surgery by publishing the definition and classification of postoperative pancreatic fistulas
Externí odkaz:
https://doaj.org/article/586181bde2b6435d85f846e82163ad79
Autor:
Francesca Simionato, Camilla Zecchetto, Valeria Merz, Alessandro Cavaliere, Simona Casalino, Marina Gaule, Mirko D’Onofrio, Giuseppe Malleo, Luca Landoni, Alessandro Esposito, Giovanni Marchegiani, Luca Casetti, Massimiliano Tuveri, Salvatore Paiella, Filippo Scopelliti, Alessandro Giardino, Isabella Frigerio, Paolo Regi, Paola Capelli, Stefano Gobbo, Armando Gabbrielli, Laura Bernardoni, Vita Fedele, Irene Rossi, Cristiana Piazzola, Serena Giacomazzi, Martina Pasquato, Morena Gianfortone, Stefano Milleri, Michele Milella, Giovanni Butturini, Roberto Salvia, Claudio Bassi, Davide Melisi
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Up-front surgery followed by postoperative chemotherapy remains the standard paradigm for the treatment of patients with resectable pancreatic cancer. However, the risk for positive surgical margins, the poor recovery after surgery that o
Externí odkaz:
https://doaj.org/article/007cd8dfb60d49e1a4d295f0e4a97c82
Autor:
Antonio Pea, Lulu Tanno, Taina Nykänen, Pooja Prasad, Ceren Tunçer, Stuart Robinson, Giovanni Marchegiani
Publikováno v:
Frontiers in Medicine, Vol 7 (2020)
Pancreatic neuroendocrine tumors (PanNETs) are rare tumors but incidence is increasing. An increasing number of these tumors are diagnosed incidentally when they are small (
Externí odkaz:
https://doaj.org/article/054cf341df3143d3b60534bc6bb95c2a
Autor:
Lulu Tanno, Antonio Pea, Taina Nykänen, Pooja Prasad, Ceren Tuncer, Giovanni Marchegiani, Stuart Robinson
Publikováno v:
Frontiers in Medicine, Vol 7 (2020)
Pancreatic neuroendocrine tumours (PNET) is a rare disease and in the absence of metastases, surgical resection is recommended. Key factors affecting survival in PNETs are the stage and grade of the disease, but there is increasing evidence suggestin
Externí odkaz:
https://doaj.org/article/81e6b3c14531429982f11343095dabb0
Autor:
Rita T. Lawlor, Paola Mattiolo, Andrea Mafficini, Seung-Mo Hong, Maria L. Piredda, Sergio V. Taormina, Giuseppe Malleo, Giovanni Marchegiani, Antonio Pea, Roberto Salvia, Valentyna Kryklyva, Jae Il Shin, Lodewijk A. Brosens, Michele Milella, Aldo Scarpa, Claudio Luchini
Publikováno v:
Cancers, Vol 13, Iss 13, p 3119 (2021)
Tumor mutational burden (TMB) is a numeric index that expresses the number of mutations per megabase (muts/Mb) harbored by tumor cells in a neoplasm. TMB can be determined using different approaches based on next-generation sequencing. In the case of
Externí odkaz:
https://doaj.org/article/48386a8ee633462490d0f8b1c7585191
Autor:
Giovanni Marchegiani, Stefano Andrianello, iuseppe Malleo, Alex Borin, Claudio Bassi, Roberto Salvia
Publikováno v:
European Medical Journal Gastroenterology, Vol 4, Iss 1, Pp 88-94 (2015)
Pancreatic cystic neoplasms (PCNs) are no longer considered as rare entities because their prevalence in the general population ranges from 3–20%. They are usually asymptomatic, incidentally discovered, and diagnosed in the seventh decade of life.
Externí odkaz:
https://doaj.org/article/7643fb9dcf6f4c9b98ff1d732b82a280